MedTrace Logo

Intrathecal Pethidine Plus Dexamethasone for Distal Lower Orthopedic Surgeries

NCT05303311 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2024-07-30

No results posted yet for this study

Summary

Bupivacaine is commonly used as a sole agent for spinal anesthesia unlike pethidine. Pethidine (meperidine) is a unique opioid. In addition to its analgesic activity, it also has significant local anesthetic activity. This property enables it to be used as the sole agent for spinal anesthesia

Conditions

  • Postoperative Pain

Interventions

DRUG

Bupivacaine Hydrochloride

intrathecal injection of bupivacaine alone

DRUG

Pethidine plus Dexamethasone

Intrathecal injection of pethidine plus dexamethasone

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Salwa S ElSherbeny, Lecturer · Zagazig University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-15
Primary Completion
2024-01-15
Completion
2024-03-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05303311 on ClinicalTrials.gov